找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract; From Surgery to Targ Eric Raymond,Sandrine Faivre,Philippe Rusznie

[復(fù)制鏈接]
查看: 23191|回復(fù): 57
樓主
發(fā)表于 2025-3-21 16:41:39 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract
副標(biāo)題From Surgery to Targ
編輯Eric Raymond,Sandrine Faivre,Philippe Ruszniewski
視頻videohttp://file.papertrans.cn/623/622557/622557.mp4
概述The latest advances in the management of neuroendocrine tumors.Multimodal approaches used for the treatment of neuroendocrine tumors of the gut.Top international experts in the field.Due to the rarity
圖書封面Titlebook: Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract; From Surgery to Targ Eric Raymond,Sandrine Faivre,Philippe Rusznie
描述.This book pursues a multidisciplinary approach, presenting chapters with updated information on various aspects of treatment for patients with neuroendocrine tumors. Authors have been selected from expert centers in Europe and the United States. The goal of this book is to comprehensively summarize recent data and provide inspiring ideas to optimize the care of patients with neuroendocrine tumors..Neuroendocrine tumors are fascinating multifaceted diseases that can primarily localize in many organs with various presentations. These tumors are rare but their increasing incidence renders likely that physicians caring for cancers may have either already faced or may be certainly exposed to diagnose and/or treat a patient with neuroendocrine tumors. Over the last years, novel therapeutic options have emerged for neuroendocrine tumors, profoundly challenging practices that had previously been the standards for decades. These include - but are not limited to - somatostatin analogues, targeted therapies such as tyrosine kinase and mTOR inhibitors, antiangiogenic compounds, but also peptide-receptor targeted therapy or radioembolization. This changing field has generated novel treatment a
出版日期Book 2014
關(guān)鍵詞Angiogenesis; Carcinoid; Pancreatic neuroendocrine tumors; Somatostatin receptors; Tyrosine kinase inhib
版次1
doihttps://doi.org/10.1007/978-2-8178-0430-9
isbn_softcover978-2-8178-0554-2
isbn_ebook978-2-8178-0430-9
copyrightSpringer-Verlag France 2014
The information of publication is updating

書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract影響因子(影響力)




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract影響因子(影響力)學(xué)科排名




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract網(wǎng)絡(luò)公開度




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract被引頻次




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract被引頻次學(xué)科排名




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract年度引用




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract年度引用學(xué)科排名




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract讀者反饋




書目名稱Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

1票 100.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:35:04 | 只看該作者
板凳
發(fā)表于 2025-3-22 03:30:47 | 只看該作者
Advances with Somatostatin Analogs in Neuroendocrine Tumors; The Promise of Radionuclides in Neuroend dual-targeting chimeric molecules. Conjugation of SST analogs with radionuclides has also been used for peptide-receptor-targeted radiotherapy (PRRT) in advanced NETs, with promising results. This chapter summarizes key preclinical and clinical data on the antisecretory and antitumor effects of S
地板
發(fā)表于 2025-3-22 05:54:29 | 只看該作者
Streptozocin-Based Chemotherapy: Still a Standard of Care for Neuroendocrine Tumours?, therapies and this may be important in those who are symptomatic from tumour burden and those with locally advanced disease who may be down-staged for resection. The role of Ki67 and other predictive markers requires further assessment in prospective studies as does the relative efficacy of alterna
5#
發(fā)表于 2025-3-22 12:23:19 | 只看該作者
6#
發(fā)表于 2025-3-22 13:46:57 | 只看該作者
Angiogenesis Inhibition Using Sunitinib in Pancreatic Neuroendocrine Tumors, trial. In this later study, sunitinib demonstrated significant benefits in terms of progression-free survival and response rate in patients with advanced well-differentiated pancreatic neuroendocrine tumors. The safety profile in this patient population was consistent with previously reported data
7#
發(fā)表于 2025-3-22 19:49:37 | 只看該作者
Clinical Management of Targeted Therapies in Neuroendocrine Tumours,ons, and providing strategies to overcome them is a further important component of patient care. At the core of clinical management is effective communication between patients and physicians, which ensures patients are fully involved in decisions concerning their care, and will allow advances in the
8#
發(fā)表于 2025-3-22 22:38:38 | 只看該作者
Imaging of Neuroendocrine Tumors and Challenges in Response Evaluation for Targeted Therapies,ving targeted agents. In this chapter, we aimed to review the various imaging techniques used to characterize neuroendocrine tumors in routine clinic and clinical trials. We also challenge the potential advantages of those imaging techniques for the evaluation of response in patients with neuroendoc
9#
發(fā)表于 2025-3-23 02:01:14 | 只看該作者
Overcoming Resistance to Targeted Therapies: The Next Challenge in Pancreatic Neuroendocrine Tumorsesponse) resistance to antiangiogenic agents and mTOR inhibitors, using data available from preclinical and clinical studies in various malignancies. Herein, we also describe how these general mechanisms of resistance may emerge in patients with PNET treated with sunitinib and everolimus. Overcoming
10#
發(fā)表于 2025-3-23 08:01:59 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-14 05:51
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
靖江市| 即墨市| 新田县| 嘉鱼县| 灵武市| 鄯善县| 郓城县| 宜宾市| 色达县| 司法| 新民市| 乐陵市| 罗平县| 丹凤县| 留坝县| 梁平县| 梅州市| 滨州市| 故城县| 措勤县| 井研县| 会昌县| 绥中县| 石景山区| 普安县| 赣州市| 海兴县| 苍梧县| 阿鲁科尔沁旗| 河北省| 遂平县| 新平| 大田县| 调兵山市| 三原县| 碌曲县| 涿州市| 顺昌县| 武陟县| 河南省| 洛宁县|